News
NNVC
1.550
+5.44%
0.080
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets
Dow Jones · 2d ago
NanoViricides Initiated at Outperform by Noble Capital Markets
Dow Jones · 2d ago
Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6
Benzinga · 2d ago
NanoViricides initiated with an Outperform at Noble Capital
TipRanks · 2d ago
NanoViricides advances towards Phase II clinical trial of NV-387
TipRanks · 2d ago
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC
Benzinga · 2d ago
Weekly Report: what happened at NNVC last week (0629-0703)?
Weekly Report · 2d ago
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
Barchart · 3d ago
NanoViricides granted Rare Pediatric Disease Drug designation for NV-387
TipRanks · 06/29 12:41
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387
Benzinga · 06/29 12:40
Weekly Report: what happened at NNVC last week (0622-0626)?
Weekly Report · 06/29 10:28
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
Barchart · 06/29 07:30
CDC raises Ebola Congo outbreak response to highest level, Reuters reports
TipRanks · 06/26 17:55
NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo
TipRanks · 06/22 13:35
NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollment For Its Phase II Clinical Trial Of Monkeypox Treatment
Benzinga · 06/22 13:33
Weekly Report: what happened at NNVC last week (0615-0619)?
Weekly Report · 06/22 10:39
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Barchart · 06/22 08:30
NanoViricides files to sell 1.33M shares of common stock for holders
TipRanks · 06/15 20:41
NanoViricides announces proposal approved by Pillar Committee in DRC
TipRanks · 06/15 12:41
NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo
Benzinga · 06/15 12:36
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.